cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.4816507
title: Risk Assessment and the Impact of Point of Contact Intervention Following Emergency Department Presentation with a Fall

description: <i>Aim:</i> To determine whether a multifactorial intervention can decrease the frequency of secondary falls in older patients presenting to an emergency department with a fall. <i>Methods:</i> A randomized control design comparing multifactorial follow-up intervention to standard care. Risk assessments included Falls Risk for Older Persons—Community Setting Screening Tool (FROP Com Screen) and the Two Item Screening Tool, which were compared for sensitivity. <i>Results:</i> Eight patients (14%) in the control group and 11 patients (20.8%) in the intervention group experienced falls (<i>p</i> = 0.373). The proportion of those identified as high risk that fell was similar between the FROP Com Screen (17%) and the Two Item Screening Tool (17%). Patients on average waited 35 days in the control group and 40 days in the intervention group for an outpatient appointment. <i>Conclusions:</i> There was no significant benefit of the intervention. Our findings support interdisciplinary collaboration, multifactorial intervention, and risk management for falls prevention.
DOI: 10.6084/m9.figshare.4816510
title: Iteration of Partially Specified Target Matrices: Application to the Bi-Factor Case

description: The current study proposes a new bi-factor rotation method, Schmid-Leiman with iterative target rotation (SLi), based on the iteration of partially specified target matrices and an initial target constructed from a Schmid-Leiman (SL) orthogonalization. SLi was expected to ameliorate some of the limitations of the previously presented SL bi-factor rotations, SL and SL with target rotation (SLt), when the factor structure either includes cross-loadings, near-zero loadings, or both. A Monte Carlo simulation was carried out to test the performance of SLi, SL, SLt, and the two analytic bi-factor rotations, bi-quartimin and bi-geomin. The results revealed that SLi accurately recovered the bi-factor structures across the majority of the conditions, and generally outperformed the other rotation methods. SLi provided the biggest improvements over SL and SLt when the bi-factor structures contained cross-loadings and pure indicators of the general factor. Additionally, SLi was superior to bi-quartimin and bi-geomin, which performed inconsistently across the types of factor structures evaluated. No method produced a good recovery of the bi-factor structures when small samples (N = 200) were combined with low factor loadings (0.30–0.50) in the specific factors. Thus, it is recommended that larger samples of at least 500 observations be obtained.
DOI: 10.6084/m9.figshare.4816510.v1
title: Iteration of Partially Specified Target Matrices: Application to the Bi-Factor Case

description: The current study proposes a new bi-factor rotation method, Schmid-Leiman with iterative target rotation (SLi), based on the iteration of partially specified target matrices and an initial target constructed from a Schmid-Leiman (SL) orthogonalization. SLi was expected to ameliorate some of the limitations of the previously presented SL bi-factor rotations, SL and SL with target rotation (SLt), when the factor structure either includes cross-loadings, near-zero loadings, or both. A Monte Carlo simulation was carried out to test the performance of SLi, SL, SLt, and the two analytic bi-factor rotations, bi-quartimin and bi-geomin. The results revealed that SLi accurately recovered the bi-factor structures across the majority of the conditions, and generally outperformed the other rotation methods. SLi provided the biggest improvements over SL and SLt when the bi-factor structures contained cross-loadings and pure indicators of the general factor. Additionally, SLi was superior to bi-quartimin and bi-geomin, which performed inconsistently across the types of factor structures evaluated. No method produced a good recovery of the bi-factor structures when small samples (N = 200) were combined with low factor loadings (0.30–0.50) in the specific factors. Thus, it is recommended that larger samples of at least 500 observations be obtained.
DOI: 10.6084/m9.figshare.4816507.v1
title: Risk Assessment and the Impact of Point of Contact Intervention Following Emergency Department Presentation with a Fall

description: <i>Aim:</i> To determine whether a multifactorial intervention can decrease the frequency of secondary falls in older patients presenting to an emergency department with a fall. <i>Methods:</i> A randomized control design comparing multifactorial follow-up intervention to standard care. Risk assessments included Falls Risk for Older Persons—Community Setting Screening Tool (FROP Com Screen) and the Two Item Screening Tool, which were compared for sensitivity. <i>Results:</i> Eight patients (14%) in the control group and 11 patients (20.8%) in the intervention group experienced falls (<i>p</i> = 0.373). The proportion of those identified as high risk that fell was similar between the FROP Com Screen (17%) and the Two Item Screening Tool (17%). Patients on average waited 35 days in the control group and 40 days in the intervention group for an outpatient appointment. <i>Conclusions:</i> There was no significant benefit of the intervention. Our findings support interdisciplinary collaboration, multifactorial intervention, and risk management for falls prevention.
DOI: 10.6084/m9.figshare.4816534.v1
title: Toegang tot de som van alle kennis

description: Middels een openbare lezing op dinsdag 4 april as van 19:00u - 21:00u in Self Reliance Tower, zal middels 3 presentaties en een paneldiscussie dit onderwerp besproken worden. De keynote spreker is Andra Waagmeester. Andra is biomedische wetenschapper en in Antwerpen (België) actief als data scientist in Micelio.tijdens de lezing “ Big Data the key to Development” zal de keynote spreker, Andra Waagmeester, uitleggen hoe open data bij kan dragen tot een betere ontsluiting van de beschikbare kennis. Dit in de twee mogelijke richtingen, namelijk (1) hoe krijg ik toegang tot beschikbare kennis/data, alsook (2) hoe deel ik mijn eigen data/kennis met een breder publiek.Anuskha Sonai zal het hebben over de trends op het gebied van Big Data en zal ingaan op het commercieel gebruik van informatie die nu open en toegankelijk is voor een ieder. Dhr. Bryan Renten zal als voorzitter van de Vereniging Surinaams Bedrijfsleven zijn inzichten delen bij de paneldiscussie. Dhr. Robert Hahn zal tijdens de paneldiscussie ook zijn mening en visie als voorzitter van de ICT Associatie Suriname delen.
DOI: 10.6084/m9.figshare.4816462
title: data_NC_HybridSolitons_upload.zip

description: The dataset contains raw data to all figures published in the manuscript entitled "Hybrid soliton dynamics in liquid-core fibres" by Chemnitz et al.
DOI: 10.6084/m9.figshare.4816438
title: Junior doctor preparedness to prescribe, monitor and treat patients with vancomycin

description: Juniors doctors self confidence and knowledge to clinically use the antibiotic vancomycin.
DOI: 10.6084/m9.figshare.4816438.v1
title: Junior doctor preparedness to prescribe, monitor and treat patients with vancomycin

description: Juniors doctors self confidence and knowledge to clinically use the antibiotic vancomycin.
DOI: 10.6084/m9.figshare.4815160
title: SSC results on real peak lists

description: Spin system grouping results of Spin System Creator program.
DOI: 10.6084/m9.figshare.4815163
title: Solution and solid-state peak lists

description: Solution-state and solid-state NMR peak lists
DOI: 10.6084/m9.figshare.4815157
title: folder_15

description: Honeybee accelerometer recordings
DOI: 10.6084/m9.figshare.4815160.v1
title: SSC results on real peak lists

description: Spin system grouping results of Spin System Creator program.
DOI: 10.6084/m9.figshare.4815046
title: iCub Facility - Ubuntu (x64) VVV VM

description: This is an Ubuntu 16.04 x64 Virtual Machine (<b>OVF format</b>) pre-configured with iCub software.<br>This VM has been prepared for the use during <b>VVV18 Winter School</b> following the instructions published here: https://github.com/vvv-school/vvv18/wiki/How-to-prepare-your-system.<br>The VM is archived within three files to comply with size limitations. Use your preferred tool to unpack the VM at once.<br><br>VM credentials are:- login: <b>icub</b>- password: <b>icub</b>
DOI: 10.6084/m9.figshare.4815049
title: Facebook & French Presidential Elections 2017

description: The files corresponding to a study conducted on Facebook in the context of the presidential elections.
DOI: 10.6084/m9.figshare.4815145
title: Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma

description: <b>Objective</b>: To evaluate safety, tolerability, and preliminary activity of inotuzumab ozogamicin (InO) plus rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) in patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma (NHL). <b>Methods</b>: Patients received InO plus R-GDP (21-day cycle; six-cycle maximum) using up-and-down dose-escalation schema for gemcitabine and cisplatin to define the highest dosage regimen(s) with acceptable toxicity (Part 1; <i>n</i> = 27). Part 2 (<i>n</i> = 10) confirmed safety and tolerability; Part 3 (<i>n</i> = 18) evaluated preliminary efficacy. <b>Results:</b> Among 55 patients enrolled, 42% were refractory at baseline (median 2 [range, 1–6] prior therapies); 38% had diffuse large B-cell lymphoma (DLBCL). The highest dosage regimen with acceptable toxicity was InO 0.8 mg/m<sup>2</sup>, rituximab 375 mg/m<sup>2</sup>, cisplatin 50 mg/m<sup>2</sup>, gemcitabine 500 mg/m<sup>2</sup> (day 1 only) and dexamethasone 40 mg (days 1–4); this was confirmed in Part 2, in which three patients had dose-limiting toxicities (grade 4 thrombocytopenia [<i>n</i> = 2], febrile neutropenia [<i>n</i> = 2]). Most frequent treatment-related adverse events were thrombocytopenia (any grade, 85%; grade ≥3, 75%) and neutropenia (69%; 62%). Overall (objective) response rate (ORR) was 53% (11 complete, 18 partial responses); ORR was 71%, 33%, and 62% in patients with follicular lymphoma (<i>n</i> = 14), DLBCL (<i>n</i> = 21), and mantle cell lymphoma (<i>n</i> = 13), respectively. <b>Conclusions:</b> InO 0.8 mg/m<sup>2</sup> plus R-GDP was associated with manageable toxicity, although gemcitabine and cisplatin doses were lower than in the standard R-GDP regimen due to hematologic toxicity. Evidence of antitumor activity was observed; however, these exploratory data should be interpreted with caution due to the small sample size and short follow-up duration (Clinicaltrials.gov number: NCT01055496).
DOI: 10.6084/m9.figshare.4815163.v1
title: Solution and solid-state peak lists

description: Solution-state and solid-state NMR peak lists
DOI: 10.6084/m9.figshare.4815145.v2
title: Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma

description: <b>Objective</b>: To evaluate safety, tolerability, and preliminary activity of inotuzumab ozogamicin (InO) plus rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) in patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma (NHL). <b>Methods</b>: Patients received InO plus R-GDP (21-day cycle; six-cycle maximum) using up-and-down dose-escalation schema for gemcitabine and cisplatin to define the highest dosage regimen(s) with acceptable toxicity (Part 1; <i>n</i> = 27). Part 2 (<i>n</i> = 10) confirmed safety and tolerability; Part 3 (<i>n</i> = 18) evaluated preliminary efficacy. <b>Results:</b> Among 55 patients enrolled, 42% were refractory at baseline (median 2 [range, 1–6] prior therapies); 38% had diffuse large B-cell lymphoma (DLBCL). The highest dosage regimen with acceptable toxicity was InO 0.8 mg/m<sup>2</sup>, rituximab 375 mg/m<sup>2</sup>, cisplatin 50 mg/m<sup>2</sup>, gemcitabine 500 mg/m<sup>2</sup> (day 1 only) and dexamethasone 40 mg (days 1–4); this was confirmed in Part 2, in which three patients had dose-limiting toxicities (grade 4 thrombocytopenia [<i>n</i> = 2], febrile neutropenia [<i>n</i> = 2]). Most frequent treatment-related adverse events were thrombocytopenia (any grade, 85%; grade ≥3, 75%) and neutropenia (69%; 62%). Overall (objective) response rate (ORR) was 53% (11 complete, 18 partial responses); ORR was 71%, 33%, and 62% in patients with follicular lymphoma (<i>n</i> = 14), DLBCL (<i>n</i> = 21), and mantle cell lymphoma (<i>n</i> = 13), respectively. <b>Conclusions:</b> InO 0.8 mg/m<sup>2</sup> plus R-GDP was associated with manageable toxicity, although gemcitabine and cisplatin doses were lower than in the standard R-GDP regimen due to hematologic toxicity. Evidence of antitumor activity was observed; however, these exploratory data should be interpreted with caution due to the small sample size and short follow-up duration (Clinicaltrials.gov number: NCT01055496).
DOI: 10.6084/m9.figshare.4814992
title: 2017 03 29 Field Notes and Comparison of Video

description: Fields notes including image and/or video records. The primary objective of this field visit was to obtain reference video for the 20 September 2014 observation of multiple animals. The original and reference videos are compared in an addendum to the field notes.<br>Project order 79a<br>
DOI: 10.6084/m9.figshare.4815145.v1
title: Phase 1 study of inotuzumab ozogamicin combined with r-gdp for the treatment of patients with relapsed/refractory cd22+ b-cell non-hodgkin lymphoma

description: <b>Objective</b>: To evaluate safety, tolerability, and preliminary activity of inotuzumab ozogamicin (InO) plus rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) in patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma (NHL). <b>Methods</b>: Patients received InO plus R-GDP (21-day cycle; 6-cycle maximum) using up-and-down dose-escalation schema for gemcitabine and cisplatin to define the highest dosage regimen(s) with acceptable toxicity (Part 1; n = 27). Part 2 (n = 10) confirmed safety and tolerability; Part 3 (n = 18) evaluated preliminary efficacy. <b>Results</b>: Among 55 patients enrolled, 42% were refractory at baseline (median 2 [range, 1–6] prior therapies); 38% had diffuse large B-cell lymphoma (DLBCL). The highest dosage regimen with acceptable toxicity was InO 0.8 mg/m<sup>2</sup>, rituximab 375 mg/m<sup>2</sup>, cisplatin 50 mg/m<sup>2</sup>, gemcitabine 500 mg/m<sup>2</sup> (day 1 only) and dexamethasone 40 mg (days 1 − 4); this was confirmed in Part 2, in which 3 patients had dose-limiting toxicities (grade 4 thrombocytopenia [n = 2], febrile neutropenia [n = 2]). Most frequent treatment-related adverse events were thrombocytopenia (any grade, 85%; grade ≥3, 75%) and neutropenia (69%; 62%). Overall (objective) response rate (ORR) was 53% (11 complete,18 partial responses); ORR was 71%, 33%, and 62% in patients with follicular lymphoma (n = 14), DLBCL (n = 21), and mantle cell lymphoma (n = 13), respectively. <b>Conclusions</b>: InO 0.8 mg/m<sup>2</sup> plus R-GDP was associated with manageable toxicity, although gemcitabine and cisplatin doses were lower than in the standard R-GDP regimen due to hematologic toxicity. Evidence of antitumor activity was observed; however, these exploratory data should be interpreted with caution due to the small sample size and short follow-up duration. (Clinicaltrials.gov number: NCT01055496).
DOI: 10.6084/m9.figshare.4814959
title: RDP ver. 11.5 database

description: RDP ver 11.5 database formatted for mg_classifier
DOI: 10.6084/m9.figshare.4815046.v1
title: iCub Ubuntu 16.04x64 Virtual Machine

description: This is an Ubuntu 16.04 x64 Virtual Machine (OVF format) pre-configured with iCub software
DOI: 10.6084/m9.figshare.4814914
title: Supplementary Material for: Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer

description: <b><i>Objective:</i></b> We clarified the predictive and prognostic value of circulating plasma exosomal microRNA-21 (miR-21) in each TNM stage of colorectal cancer (CRC) patients. <b><i>Methods:</i></b> The microRNA (miRNA) profiles of the plasma exosomes, primary tumor tissues, and liver metastasis tissues from the same CRC patients were examined using a microarray. For validation analysis, the plasma exosome samples from 326 CRC patients were measured by TaqMan miRNA assays. <b><i>Results:</i></b> In the miRNA microarray analyses, miR-21 showed the highest upregulation in exosomes, primary tumor tissues, and liver metastasis tissues. Significant correlations were demonstrated between exosomal miR-21 and tissue miR-21 levels. As for the relationship to the pathological condition, exosomal miR-21 showed a significant association with liver metastasis and TNM stage. The overall survival (OS) rates and disease-free survival (DFS) rates in high-exosomal-miR-21 patients were significantly worse than those in low-miR-21 patients. Exosomal miR-21 levels were an independent prognostic factor for OS and DFS in CRC patients with TNM stage II or III, and for OS in patients with TNM stage IV. <b><i>Conclusion:</i></b> Plasma exosomal miR-21 levels are a useful biomarker for the prediction of recurrence and poor prognosis in CRC patients with TNM stage II, III, or IV.
DOI: 10.6084/m9.figshare.4814917
title: Supplementary Material for: Inducible GBP5 Mediates the Antiviral Response via Interferon-Related Pathways during Influenza A Virus Infection

description: Guanylate binding protein (GBP) 5 belongs to the GBP family, which is involved in important cellular processes, including signal transduction, translation, vesicle trafficking, and exocytosis. Structurally, GBPs display a high degree of homology and share highly conserved GTP-binding or hydrolysis domains. GBP5 was reported to be a critical cellular factor in inflammasome assembly. However, little is known about its role in the host antiviral innate immune response. In this study, we found that GBP5 expression was significantly elevated in influenza patients and influenza A virus-infected A549 human lung epithelial cells. The overexpression of GBP5 inhibited virus replication by enhancing the expression of virus-induced interferon (IFN) and IFN-related effectors. Knockdown of GBP5 had the opposite effect. Moreover, GBP5 enhanced endogenous IFN expression by interacting with the NF-κB-essential modulator complex and stimulating NF-κB signaling. Additionally, the expression of proinflammatory factors, such as IL-6, IL-8, tumor necrosis factor-α, cyclooxygenase-2, and inducible nitric oxide synthase, was also activated by GBP5. Taken together, our results reveal that GBP5 inhibited virus replication through the activation of IFN signaling and proinflammatory factors.
DOI: 10.6084/m9.figshare.4814839
title: Dataset for: Generalised additive point process models for natural hazard occurrence

description: Point processes are a natural class of model for representing occurrences of various types of natural hazard event. Flexibly implementing such models is often hindered by intractable likelihood forms. Consequently, rates of point processes tend to be reduced to parametric forms, or the processes are discretised to give data of readily modelled `count-per-unit' type. This work proposes generalised additive model forms for point process rates. The resulting low-rank spatio-temporal representations of rates, coupled with the Laplace approximation, makes the restricted likelihood relatively tractable, and hence inference for such models possible. The models can also be interpreted from a regression perspective. The proposed models are used to estimate different types of Cox process and then spatio-temporal variation in European windstorms. Through a combination of thin plate and cubic regression splines, and their tensor product, established relationships between where windstorms occur and the state of the North Atlantic Oscillation are confirmed, and then expanded to bring detailed understanding of within-year variation, which has otherwise not been possible with count-based models.
DOI: 10.6084/m9.figshare.4814827
title: Semantic typing of linked geoprocessing workflows

description: In Geographic Information Systems (GIS), geoprocessing workflows allow analysts to organize their methods on spatial data in complex chains. We propose a method for expressing workflows as linked data, and for semi-automatically enriching them with semantics on the level of their operations and datasets. <i>Linked workflows</i> can be easily published on the Web and queried for types of inputs, results, or tools. Thus, GIS analysts can reuse their workflows in a modular way, selecting, adapting, and recommending resources based on compatible semantic types. Our typing approach starts from minimal annotations of workflow operations with classes of GIS tools, and then propagates data types and implicit semantic structures through the workflow using an OWL typing scheme and SPARQL rules by backtracking over GIS operations. The method is implemented in Python and is evaluated on two real-world geoprocessing workflows, generated with Esri's ArcGIS. To illustrate the potential applications of our typing method, we formulate and execute competency questions over these workflows.
DOI: 10.6084/m9.figshare.4814827.v1
title: Semantic typing of linked geoprocessing workflows

description: In Geographic Information Systems (GIS), geoprocessing workflows allow analysts to organize their methods on spatial data in complex chains. We propose a method for expressing workflows as linked data, and for semi-automatically enriching them with semantics on the level of their operations and datasets. <i>Linked workflows</i> can be easily published on the Web and queried for types of inputs, results, or tools. Thus, GIS analysts can reuse their workflows in a modular way, selecting, adapting, and recommending resources based on compatible semantic types. Our typing approach starts from minimal annotations of workflow operations with classes of GIS tools, and then propagates data types and implicit semantic structures through the workflow using an OWL typing scheme and SPARQL rules by backtracking over GIS operations. The method is implemented in Python and is evaluated on two real-world geoprocessing workflows, generated with Esri's ArcGIS. To illustrate the potential applications of our typing method, we formulate and execute competency questions over these workflows.
DOI: 10.6084/m9.figshare.4814839.v1
title: Dataset for: Generalised additive point process models for natural hazard occurrence

description: Point processes are a natural class of model for representing occurrences of various types of natural hazard event. Flexibly implementing such models is often hindered by intractable likelihood forms. Consequently, rates of point processes tend to be reduced to parametric forms, or the processes are discretised to give data of readily modelled `count-per-unit' type. This work proposes generalised additive model forms for point process rates. The resulting low-rank spatio-temporal representations of rates, coupled with the Laplace approximation, makes the restricted likelihood relatively tractable, and hence inference for such models possible. The models can also be interpreted from a regression perspective. The proposed models are used to estimate different types of Cox process and then spatio-temporal variation in European windstorms. Through a combination of thin plate and cubic regression splines, and their tensor product, established relationships between where windstorms occur and the state of the North Atlantic Oscillation are confirmed, and then expanded to bring detailed understanding of within-year variation, which has otherwise not been possible with count-based models.